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Abstract: High plasma homocysteine levels are a known risk factor in heart failure and sudden 
cardiac death. The G proteins, Gs (stimulatory) and Gi (inhibitory), are involved in calcium regu-
lation; overexpression has pathological consequences. The aims of this study were to examine 
the differential expression of Gs G protein and Gi in the hearts of hyperhomocysteinemic (Hhcy) 
mice, and to determine if homocysteine (Hcy) acts as an agonist in cell culture to mediate the 
change in G protein isoforms. To create Hhcy, heterozygous cystathionine-β-synthase (CBS) 
knockout (KO) mice were used. Mice were sacriﬁ  ced, hearts were excised, cardiac tissue 
homogenates were prepared, and Western blots were performed. The results suggested that Gs 
G protein was downregulated in cardiac tissue of heterozygous CBS KO mice to 46% that of 
control hearts. However, the intracellular Gi G protein content remained the same in heterozygous 
CBS KO mice. Transformed cardiomyocyte HL-1 cells were treated with varying concentra-
tions of homocysteine. The results suggested no detectable differential Gs and Gi expression. 
This suggested that Hcy did not act as an agonist in vitro to alter G protein content, but that 
Hcy produced some other in vivo effects to incur these results.
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Introduction
Homocysteine (Hcy) is a nonprotein amino acid. It differs from cysteine only in its side 
chain that contains an additional methylene group before the thiol group.1,2 Moreover, 
Hcy is the result of methionine metabolism and is converted to cystathionine by cysta-
thionine-β-synthase (CBS); an established model for creating hyperhomocysteinemia 
(Hhcy) is with heterozygous CBS knockout mice (CBS KO mice) since these mice are 
unable to convert Hcy to cystathionine, resulting in excess levels of plasma Hcy.3
A high plasma Hcy level has recently been suggested to be a major risk factor sur-
rounding chronic heart failure (CHF).4–9 Recently, Hcy has been shown to increase ERK 
phosphorylation in cultured microvascular endothelial cells (MVEC).10 Hcy-induced 
ERK phosphorylation was suppressed by pertussis toxin (PTX).10 Since PTX is known 
to block Gi and Gq-mediated pathways, this suggested the involvement of G protein-
coupled receptors (GPCRs) in initiating signal transduction by Hcy that leads to ERK 
activation.10 GPCRs are integral membrane-spanning proteins that have G proteins 
attached intracellularly; upon activation of a GPCR by an agonist, the G-proteins detach 
from the receptor and proceed to activate other effectors.11 There is a large class of 
GPCRs that utilize a great variety of different G proteins. Cardiac-adrenergic receptors 
are an example of GPCRs that are important regulators of cardiac function.12
Stimulation of GPCRs can occur with the following: sympathetic or parasympa-
thetic neuronal activation, by circulating catecholamines, by adrenergic agonists that 
increase heart rate (chronotropism), force of cardiac contraction (inotropism), rate 
of cardiac relaxation (lusitropism), and automaticity.12 The prominent β1 subtype is 
mainly responsible for positive chronotropic and inotropic effects of catecholamines.13 Vascular Health and Risk Management 2009:5 80
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Activation of a GPCR coupled to Gs increases the activity 
of adenylyl cyclase and increases intracellular calcium 
concentration.12 Calcium is a known modulator of cardiac 
function.
Net G protein content available for signaling is impera-
tive for maintaining homeostasis. Many studies indicate 
cardiomyopathy from overexpression of G proteins. Cultured 
neonatal cardiac myocytes from transgenic mice overexpress-
ing cardiac G showed a ﬁ  ve-fold higher Icalcium compared with 
wild type controls.14 In TG mice overexpressing the Gs sub-
unit, heart rate and left ventricular ejection fraction (LVEF) 
was elevated compared with littermate wild-type mice.15
In summary, there is an association of high plasma Hcy 
levels and heart failure.4–9
Moreover, calcium regulation is crucial to cardiac func-
tion. Evidence from our lab suggested the involvement of 
GPCRs in modulating calcium-induced ERK activation 
in MVEC.10 Moreover, Gs and Gi are fundamental effec-
tors that regulate calcium homeostasis in cardiomyocytes; 
overexpression can result in pathology.12,14,15 We, therefore, 
hypothesized that high plasma Hcy levels could modulate net 
G protein content available for signaling in cardiomyocytes 
in vitro and in vivo, thereby modulating calcium homeostasis. 
Moreover, we were unsure whether content would increase 
or decrease since our results could indicate a contribution or 
mitigation to cardiomyopathy. Cultured HL-1 transformed 
cardiomyocytes were used as models for cardiac response to 
determine if homocysteine acts as an agonist in isolation to 
alter G protein content and if these results could be replicated 
in a more complex living system.
Materials and methods
Animals
All animal procedures were in accordance with the National 
Institute of Health Guidelines for animal research and were 
approved by the Institutional Animal Care and Use Com-
mittee of the University Of Louisville School Of Medicine. 
There were 4 mice used in each of 2 groups: control, CBS 
KO. The CBS KO mice used were also used in a previous 
study: 3-Deazaadenosine mitigates arterial remodeling and 
hypertension in hyperhomocysteinemic mice.16 Wild-type 
(WT; B6.129PF2/J) and breeding pairs of CBS heterozy-
gote (–/+) knockout (CBSKO; B6.129P2-Cbstm1Unc) mice 
aged 8–12 wks were obtained from Jackson Laboratories 
(Bar Harbor, ME). Mice were bred at the breeding facility 
at University of Louisville School of Medicine. Homozy-
gous mutants, completely lacking CBS, have 40- to 50-fold 
higher plasma Hcy levels and a very short life span; hence, 
they were not used for the study. In this study, we used 
male heterozygous animals with plasma Hcy levels between 
25 and 30 μM, a well established model of HHcy. Each group 
received a standard lab chow for that duration. After 12 weeks 
of treatment, mice were sacriﬁ  ced, hearts were excised and 
stored at −70 °C until further experimentation. Homogenates 
were prepared from ventricle of the hearts.
Plasma Hcy measurements
The level of Hcy in plasma was quantitatively analyzed with 
the Bio-Rad microplate enzyme immunoassay homocysteine 
assay (Bio-Rad Laboratories, Hercules, CA) and a Spectra-
Max M2 Analyzer (Molecular Devices, Sunnyvale, CA) 
according to the manufacturers’ instructions to ensure Hcy 
levels of CBS KO were between 25 and 30 μM.
Chemicals
The antibodies against Gs and Gi were obtained from Santa 
Cruz (Santa Cruz, CA). The antibody against-actin was 
obtained from Sigma (St. Louis, MO). Plain DMEM/F-
12 50/50 medium was obtained from Mediatech, Inc 
(Herndon, VA). Fetal Bovine Serum was acquired from 
Gemini Bio-Products, (West Sacramenta, CA). Claycomb 
medium with penicillin, streptomycin, trypsin-EDTA, and 
Hanks’ balanced salt solution (HBSS) were purchased from 
GIBCO-BRL (Grand Island, NY); DL-Hcy, NaCl, sodium 
orthovanadate, Tris, EDTA, EGTA, dithiothreitol, NP-40, 
protease inhibitor cocktail, ﬁ  bronectin, agarose, from Sigma 
(St. Louis, MO); D,L-homocysteine was obtained from Sigma 
(St. Louis, MO).
Cell culture and treatments
Cultured HL-1 cells were received as a gift from LSU, 
(New Orleans, LA) The complete Claycomb medium was 
supplemented with sterile 100 μM norepinephrine bitartrate 
(10 mL/L of a 10 mM norepinephrine stock solution), 4 mM 
L-glutamine (Catalog No. 59202C) and 10% FBS prior to 
use. A T-25 ﬂ  ask was coated with ﬁ  bronectin overnight 
before plating cells. Cells were grown to near conﬂ  uence, 
and serum starved overnight when treated with the indicated 
reagents for Western blot analysis. Claycomb Medium is 
designed for use in a 5% CO2 humid environment. HL-1 
cells require higher than normal cell densities for optimal 
growth and behavior.
Preparation of samples, Western blot analysis,
and immunodetection
After treatment, medium was aspirated from six-well 
culture dishes and HL-1 were washed twice with ice-cold Vascular Health and Risk Management 2009:5 81
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1 × PBS. Ice-cold lysis buffer (in mM: 50 Tris⋅HCl, 
pH 7.4, 150 NaCl, 1% Triton X-100, and 1 EGTA) 
and freshly prepared inhibitors (1 mM PMSF, 1 μg/ml 
leupeptin, 200 μM sodium orthovandate, and 1 μg/ml 
aprotinin) were added to each well. Plates were scraped on 
ice, and the supernatant containing cytosolic protein was 
collected and centrifuged at 5500 g for 10 min at 4 °C, and 
resolved by SDS-PAGE on 10% polyacrylamide gels and 
blotted onto a polyvinylidene diﬂ  uoride membrane. After 
being transferred, blots were washed with Tris-buffered 
saline (TBS) for 5 min at room temperature and incubated 
in blocking buffer for 1 h at room temperature. The blots 
were then incubated with the indicated primary antibodies 
[appropriate dilutions in 3% Milk solution of TBST, (0.1% 
Tween 20 + TBS: TBST)] overnight at 4 °C using gentle 
agitation. The blots were washed four times (5-min wash 
each time) with TBST and incubated with HRP-conjugated 
secondary antibody (1:3,000 dilution in 3% Milk-TBST). 
After being washed with TBST 4 times (10 minutes wash 
each time), the proteins of interest were detected using an 
ECL plus kit (Amersham Biosciences, Piscataway, NJ). 
The membranes were then stripped using 0.2 M NaOH 
solution for 30 min at room temperature and reprobed with 
a standard, -actin.
Statistical analysis
Statistical analysis was performed using an unpaired 
Student’s t-test for comparison between control, Hcy, and 
other pharmacological treatment groups. P  0.05 was con-
sidered statistically signiﬁ  cant. All results are averages ± SE 
of at least three different experiments.
Results
We report that Gs expression in left ventricular heart tis-
sue decreased to 46% of the control value of expression 
(P  0.01, n = 4) (Figure 1). Gi expression remained 
unchanged in heart homogenates of both CBS KO mice 
and wild type mice. Equal protein concentration was deter-
mined using Bradford dye experiment, while equal loading 
was conﬁ  rmed using -actin.
The level of Gs expression and Gi expression remained 
the same in HL-1 transformed cardiomyocytes cultured cells 
treated with the following concentrations of Hcy for 24 hours: 
0 μM, 25 μM, 50 μM, 100 μM, 500 μM. There were no sig-
niﬁ  cant changes in expression (P  0.05, n = 3) (Figure 2).
Discussion
There is a consistent association of high plasma Hcy with 
clinical and echocardiographic measures of CHF.9 In fact, 
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Figure 1 In vivo G protein content of Gs and Gi in wild type and CBS KO mice. β-actin was used as a standard for both protein samples. Gs content in CBS KO mice was 
reduced to 46% (P  0.01, n = 4) that of control values based on 3 different tissue homogenates. Pixel intensity was digitized using UnScanIt Software.Vascular Health and Risk Management 2009:5 82
Vacek et al
data suggested that Hhcy is not only associated with an 
increased incidence of CHF, but also with severity of dis-
ease.4 Moreover, Hhcy could evoke cardiac remodeling that 
features interstitial and perivascular ﬁ  brosis.4 The presence 
of elevated plasma Hcy is also an independent predictor of 
progression of coronary plaque load that results in atheroscle-
rosis.7 In heart failure, the sympathetic system is activated, 
cardiac receptor number and function are decreased, and 
downstream mechanisms are altered.13 Our CBS KO mice 
demonstrated indicators of heart failure such as hypertension, 
hypertrophy, and arterial remodeling.16 It is important to note 
that metabolic, structural and functional effects on the heart 
may differ fundamentally if Hhcy is induced by methionine, 
homocystine or B-vitamin deﬁ  ciency.
Downregulation of GPCRs can clearly result in differ-
ences of G protein content since G proteins are attached to 
their respective receptors via cytoplasmic C-terminal and 
cytoloops.17–19 Several studies show differential β-adrenergic 
downregulation in conjunction with the differential G protein 
expression that we observed in vivo. The decrease resulted 
from receptor internalization, sequestration, and consump-
tion.20 In a study using a pacing tachycardia HF model in 
canines, HF resulted in a uniform reduction in β1-AR density 
in surface and T-tubule membrane.21 In a pulmonary in vivo 
model of β2-adrenoceptor desensitization and internaliza-
tion, it was found that albuterol or salmeterol induced a 
downregulation of Gs.22,23 Another ﬂ  uorescent study of Gs 
showed that internalization of β2 adrenergic receptors and 
Gs subunit occurs simultaneously, providing another link 
for receptor downregulation occurring in conjunction with 
differential G protein content.24
It is important to note that there are several GPCRs that 
utilize the Gs and Gi G proteins other than the β-adrenergic 
receptors.25 It is likely that the decrease in Gs can be attributed 
to downregulation of several different GPCRs that utilize 
this G protein. Western blot analysis showed Gs content is 
decreased to 46% that of control levels in CBS KO mice 
(Figure 1).
Varying levels of G proteins and GPCRs can inﬂ  u-
ence cardiomyopathy. The result of a disrupted balance of 
β-ARs can be seen in a study of TG mice overexpressing 
β1-adrenoceptors that encounter mortality sooner.26 β-AR 
blockage by propranolol treatment was salutatory in these TG 
mice, and can prevent the development of cardiomyopathy.27 
The model of volume overload cardiac hypertrophy produced 
our same results for CBS KO mice: decreased content of 
Gs, but not of Gi in heart.28 These results have a clear link to 
Hcy-induced CHF and hypertrophy; it is already known Hhcy 
leads to pathological ventricular hypertrophy in normotensive 
rats.new1 Clinical and experimental studies have indicated a 
role of homocysteine in ventricular hypertrophy via angio-
tensin II mechanism.new2 Moreover, a human study showed 
an association between plasma homocysteine concentrations 
and cardiac hypertrophy in end-stage renal disease.7,31
G protein content is important for proper cardiac function. 
It was found that activation of Gs via β-adrenergic receptors 
Homocysteine Treatment HL-1 Cells
R
e
l
a
t
i
v
e
 
t
o
 
C
o
n
t
r
o
l
Concentration Hcy (μM)
Gαs HL-1
Gαi HL-1
β-actin
0
0
0.8
1.6
0
0.8
1.6
GαsHL-1
Gαi HL-1
500 100 50 25
Figure 2 In vitro G protein content of Gs and Gi in serum-starved HL-1 cells using the following concentrations for 24 hours: 0 μM, 25 μM, 50 μM, 100 μM, 500 μM. No 
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enhanced the activity of cardiac voltage-dependent Ca2+ 
channels of the L-type.33 One other study showed TG mice 
with cardiac Gs overexpression exhibited enhanced inotropic 
and chronotropic responses to sympathetic stimulation, and 
TG mice developed cardiomyopathy with age. Other TG 
models with selective induction of Gi subunit expression 
showed novel downstream events in hypertrophic signaling 
that could be critical factors leading to cellular electrophysi-
ological remodeling and cardiac arrhythmias in hypertrophic 
cardiomyopathy.32
Hcy treatment of HL-1 transformed cardiomyocytes at 
varying doses for 24 hours produced no detectable changes 
in intracellular Gs or Gi protein content, which suggested that 
downregulation of any GPCRs utilizing these G proteins did 
not occur in isolated treatment of Hcy agonist (Figure 2). It 
is known that treatment of cells with receptor agonists for 
many minutes or hours results in a loss of cellular receptors 
(downregulation).6 Hence, this treatment would have been 
sufﬁ  cient to evoke receptor downregulation and variable 
G protein content if Hcy is, indeed, an agonist to GPCRs 
utilizing these G proteins. Since this is not the case, this sug-
gested that Hcy does not act as an agonist to evoke GPCR 
downregulation and modulate Gs content. Therefore, this 
suggested that Hcy acts via some other mechanism in vivo 
to evoke differential Gs content.
Conclusion
Results indicated that Gs is the only G protein of interest 
decreased in vivo, this limits available Gs for calcium 
signaling. Moreover, our results suggested a compensatory 
decrease of calcium signaling via G protein pathway in spite 
of greater chronotropy and ionotropy characteristic of heart 
failure. Moreover, Hcy did not act as an agonist in vitro to 
incur differential G protein content, which suggested that 
Hcy incurs some other in vivo effects that lead to a decrease 
in Gs in the living system.
Limitations
We did not test whether the levels of expression of G protein 
isoforms of interest are the same in CBS KO mice at the early 
stage (normal cardiac function) and at the late stage (heart 
failure); this could have served as another control to ensure the 
CBS gene did not affect G protein isoforms. Our interest in this 
study laid in determining net G protein content available for 
signaling before discovering which GPCRs that contain the 
respective G proteins are modulated. We speculate that β1-AR 
downregulation, which contains Gs G protein, is responsible 
for our measured decrease in Gs G protein in in vivo data since 
β1-AR is consistently downregulated in cases of heart failure 
(Figure 3). Since HL-1 cells are known to demonstrate the same 
phenotype as primary culture cardiomyocytes, we did not view 
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Figure 3 Proposed in vivo model G protein content based on decrease in Gs content. High homocysteine levels created by CBS KO model decreased Gs content available for 
calcium signaling.   A decrease in Gs content decreased chronotropic and ionotropic response to circulating GPCR agonists that utilize this G protein.Vascular Health and Risk Management 2009:5 84
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this as a limitation. The duration of time for treatment in vitro 
(24 hours) was chosen since it is known that treatment of cells 
with receptor agonists for many minutes or hours resulted in a 
loss of cellular receptors (downregulation).6 If downregulation 
is going to occur, it is likely to be captured within this period 
of time.
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